<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Esomeprazole</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00736</strong>&#160; (APRD00363)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and zollinger-ellison syndrome. The drug inhibits the H(<ins>)-K(</ins>)-ATPase (H(<ins>)-K(</ins>)-exchanging ATPase) in the proton pump of gastric parietal cells. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00736/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00736/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00736.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00736.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00736.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00736.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00736.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00736">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(-)-Omeprazole</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>(S)-Omeprazole</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Esomeprazol</td><td>German/Spanish</td><td>INN</td></tr><tr><td>&#201;som&#233;prazole</td><td>French</td><td>INN</td></tr><tr><td>Esomeprazolum</td><td>Latin</td><td>INN</td></tr><tr><td>Perprazole</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Esomeprazole Sodium</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000968/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000968/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000968">DBSALT000968</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Alenia</td><td>Delta</td></tr><tr><td>Awa-Block</td><td>Usawa</td></tr><tr><td>Axagon</td><td>Simesa</td></tr><tr><td>Cor</td><td>Prater</td></tr><tr><td>Cronopep</td><td>Biotoscana</td></tr><tr><td>Emanera</td><td>Krka</td></tr><tr><td>Emep</td><td>Aristopharma</td></tr><tr><td>Emozul</td><td>HYGIA</td></tr><tr><td>ES-OD</td><td>Piramal Healthcare</td></tr><tr><td>Esmep</td><td>HYGIA</td></tr><tr><td>Eso</td><td>Asiatic Lab</td></tr><tr><td>Esofag</td><td>Micro Labs</td></tr><tr><td>Esogastrosedol</td><td>Nova Argentia</td></tr><tr><td>Esolok</td><td>Ibn Sina</td></tr><tr><td>Esomarfan</td><td>Marfan</td></tr><tr><td>Esomenta</td><td>RAK</td></tr><tr><td>Esomep</td><td>ACI</td></tr><tr><td>Esomeprazol Genfar</td><td>Genfar S.A</td></tr><tr><td>Esopral</td><td>Maquifarma</td></tr><tr><td>Esorest</td><td>Centaur</td></tr><tr><td>Lucen</td><td>Malesci</td></tr><tr><td>Nexiam</td><td>AstraZeneca</td></tr><tr><td>Nexium</td><td>AstraZeneca</td></tr><tr><td>Nexium i.v.</td><td>AstraZeneca</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Axanum</td><td>Esomeprazole and Acetylsalicylic Acid</td></tr><tr><td>Esofag-D</td><td>Esomeprazole and Domperidone</td></tr><tr><td>Neutraflux</td><td>Esomeprazole and Domperidone</td></tr><tr><td>Vimovo</td><td>Esomeprazole and Naproxen</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/proton-pump-inhibitors">Proton Pump Inhibitors</a></li>
<li><a href="/mesh/histamine-antagonists">Histamine Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>161796-78-7</td></tr><tr><th>Weight</th><td>Average: 345.416<br>Monoisotopic: 345.114712179</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S</td></tr><tr><th>InChI Key</th><td>SUBDBMMJDZJVOS-XMMPIXPASA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5-methoxy-2-[(R)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl]-1H-1,3-benzodiazole</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=CC2=C(NC(=N2)[S@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzimidazoles</td></tr><tr><th>Subclass</th><td>Sulfinylbenzimidazoles</td></tr><tr><th>Direct parent</th><td>Sulfinylbenzimidazoles</td></tr><tr><th>Alternative parents</th><td>Anisoles; Alkyl Aryl Ethers; Pyridines and Derivatives; Imidazoles; Sulfoxides; Polyamines</td></tr><tr><th>Substituents</th><td>phenol ether; anisole; alkyl aryl ether; pyridine; benzene; imidazole; azole; sulfoxide; ether; polyamine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.</td></tr><tr><th>Pharmacodynamics</th><td>Esomeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and <i>H. pylori</i> eradication to reduce the risk of duodenal ulcer recurrence. Esomeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup> ATPase at the secretory surface of the gastric parietal cell. By doing so, it inhibits acid secretion into the gsatric lumen. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.</td></tr><tr><th>Mechanism of action</th><td>Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup>-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Esomeprazole blocks the final step in acid production, thus reducing gastric acidity.</td></tr><tr><th>Absorption</th><td>90%</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>16 L [healthy volunteers]</li>
</ul></td></tr><tr><th>Protein binding</th><td>97%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Mainly hepatic. Esomeprazole is completely metabolized by the cytochrome P450 system via CYP2C19 and CYP3A4. Metabolism produces inactive hydroxy and desmethyl metabolites, which have no effect on gastric acid secretion. Less than 1% of the parent drug is excreted in urine. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Esomeprazole</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00448">5-hydroxyesomeprazole</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/457">Details</a></td></tr><tr><td>Esomeprazole</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01164">Active Metabolite of Esomeprazole</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1299">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Approximately 80% of the administered dose of esomeprazole is excreted as metabolites in urine and the remaining 20% is excreted in feces. </td></tr><tr><th>Half life</th><td>1-1.5 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Blurred vision, confusion, drowsiness, dry mouth, flushing headache, nausea, rapid heartbeat, sweating</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Esomeprazole Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00225?highlight%5Bcompounds%5D%5B%5D=DB00736&amp;highlight%5Bproteins%5D%5B%5D=DB00736">SMP00225</a></td></tr><tr><td>Esomeprazole Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00612?highlight%5Bcompounds%5D%5B%5D=DB00736&amp;highlight%5Bproteins%5D%5B%5D=DB00736">SMP00612</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cytochrome P450 2C19<br>Gene symbol: CYP2C19<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P33261" target="_blank">P33261 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs4244285" target="_blank">rs4244285 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2C19*2</td><td>A Allele, homozygote</td><td>Poor metabolizer, lower dose requirement, improved drug efficacy</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/9867757" target="_blank" title="Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998 Dec 15;129(12):1027-30.">9867757 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Cytochrome P450 2C19<br>Gene symbol: CYP2C19<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P33261" target="_blank">P33261 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs4986893" target="_blank">rs4986893 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2C19*3</td><td>A Allele, homozygote</td><td>Poor metabolizer, lower dose requirement, improved drug efficacy</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/9867757" target="_blank" title="Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998 Dec 15;129(12):1027-30.">9867757 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9968</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.6326</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5573</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.6622</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.968</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.542</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7838</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.6175</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6901</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.7505</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.7895</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5692
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8318
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9778
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2254 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.719
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8977
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Astrazeneca lp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Direct Pharmaceuticals Inc.</li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule, delayed release</td><td>Oral</td><td>20 mg</td></tr><tr><td>Capsule, delayed release</td><td>Oral</td><td>40 mg</td></tr><tr><td>Granule, for suspension</td><td>Oral</td><td>10 mg per packet</td></tr><tr><td>Granule, for suspension</td><td>Oral</td><td>20 mg per packet</td></tr><tr><td>Granule, for suspension</td><td>Oral</td><td>40 mg per packet</td></tr><tr><td>Injection</td><td>Intravenous</td><td>20 mg</td></tr><tr><td>Injection</td><td>Intravenous</td><td>40 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Nexium i.v. 20 mg vial</td><td>33.91USD</td><td>vial</td></tr><tr><td>Nexium i.v. 40 mg vial</td><td>33.91USD</td><td>vial</td></tr><tr><td>NexIUM 20 mg Delayed Release Capsule</td><td>6.76USD</td><td>capsule</td></tr><tr><td>NexIUM 40 mg Delayed Release Capsule</td><td>6.76USD</td><td>capsule</td></tr><tr><td>Nexium 10 mg packet</td><td>6.5USD</td><td>each</td></tr><tr><td>Nexium 20 mg capsule</td><td>6.5USD</td><td>capsule</td></tr><tr><td>Nexium 20 mg packet</td><td>6.5USD</td><td>each</td></tr><tr><td>Nexium 40 mg capsule</td><td>6.5USD</td><td>capsule</td></tr><tr><td>Nexium 40 mg packet</td><td>6.5USD</td><td>each</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6428810</td><td>2000-05-03</td><td>2020-05-03</td></tr><tr><td>United States</td><td>5877192</td><td>1994-05-27</td><td>2014-05-27</td></tr><tr><td>Canada</td><td>2346988</td><td>2009-02-10</td><td>2019-11-03</td></tr><tr><td>Canada</td><td>1338377</td><td>1996-06-11</td><td>2013-06-11</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>155 &#176;C</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>water solubility</td><td>Very slightly soluble in water</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>0.6</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>3.53e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.66</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.43</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>9.68</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>4.77</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>77.1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>93.66</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>37.43</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Manne Reddy, &#8220;Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof.&#8221; U.S. Patent US20040167173, issued August 26, 2004.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=20040167173&amp;tbm=pts" target="_blank">US20040167173 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Rohss K: Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000 Jul;14(7):861-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10886041">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D01984" target="_blank">D01984 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=50275" target="_blank">50275 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201320" target="_blank">CHEMBL1201320 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000524" target="_blank">DCL000524 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA10075" target="_blank">PA10075 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=4279" target="_blank">4279 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4279" target="_blank">4279 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2244521" target="_blank">2244521 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic3/esomeprazole.htm" target="_blank">http://www.rxlist.com/cgi/generic3/esomeprazole.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/esomeprazole.html" target="_blank">http://www.drugs.com/cdi/esomeprazole.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Esomeprazole" target="_blank">Esomeprazole <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>AHFS Codes</th><td><ul><li>56:28.36</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00736.pdf?1265922808">show</a>(104 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB01066">Cefditoren</a></td><td>Proton pump inhibitors such as esomeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.</td></tr><tr><td><a href="/drugs/DB00758">Clopidogrel</a></td><td>Esomeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent esomeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with esomeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel. </td></tr><tr><td><a href="/drugs/DB00467">Enoxacin</a></td><td>Esomeprazole may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Omeprazole decreases the absorption of indinavir</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>The proton pump inhibitor, esomeprazole, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>The proton pump inhibitor, esomeprazole, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB08864">Rilpivirine</a></td><td>Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Esomeprazole. Consider alternate therapy or increase the dose of Esomeprazole based on the therapeutic response.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>